Priyanka Rohatgi is an entrepreneurial business leader with over a decade of experience in venture capital, pharmaceutical, biotechnology, and medical device industries. She advises Radyus clients on fundraising and business development activities. She leverages her deep expertise in venture capital, business development, and scientific research to build innovative companies with talented entrepreneurs.

Priyanka's core strengths include deal structuring, negotiations, and managing portfolio companies to maximize shareholder value. Previously, she held leadership roles at Novo Ventures, Longwood Fund, Ipsen Ventures, AbbVie Ventures, and Baxter Ventures. Priyanka also served as a board member/observer for several biotech companies, including Artios Pharma, Jnana (acquired by Otsuka), Interius BioTherapeutics, Mirna (NASDAQ: MIRN), Naurex (acquired by Allergan), Precision Bioscience (NASDAQ: DTIL), Pyxis Oncology (NASDAQ: PYXS), Sanifit (acquired by Vifor Pharma), Syntimmune (acquired by Alexion), and Xilio Therapeutics (NASDAQ: XLO).

With an impressive academic background, Priyanka holds advanced degrees in pharmacokinetics, biochemistry, and computational biology from top institutions such as the University of Washington, Georgia Institute of Technology, and Delhi University. She has received numerous accolades, including the Global Venture Capitalist Rising Star Award and the Baxter Technology Resources R&D Outstanding Achievement Award, in recognition of her contributions to the industry.